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Abstract
Background: Pneumonia is the 2nd leading cause of years of life lost worldwide and is a common cause of adult
admissions to hospital in sub-Saharan Africa. Risk factors for adult pneumonia are well characterised in developed
countries, but are less well described in sub-Saharan Africa where HIV is a major contributing factor. Exposure to
indoor and outdoor air pollution is high, and tobacco smoking prevalence is increasing in sub-Saharan Africa, yet
the contribution of these factors to the burden of chronic respiratory diseases in sub-Saharan Africa remains poorly
understood. Furthermore, the extent to which the presence of chronic respiratory diseases and exposure to air
pollution contribute to the burden of pneumonia is not known.
Design: The Acute Infection of the Respiratory Tract Study (The AIR Study) is a case–control study to identify
preventable risk factors for adult pneumonia in the city of Blantyre, Malawi. Cases will be adults admitted with
pneumonia, recruited from Queen Elizabeth Central Hospital, the largest teaching hospital in Malawi. Controls will
be adults without pneumonia, recruited from the community. The AIR Study will recruit subjects and analyse data
within strata defined by positive and negative HIV infection status. All participants will undergo thorough
assessment for a range of potential preventable risk factors, with an emphasis on exposure to air pollution and the
presence of chronic respiratory diseases. This will include collection of questionnaire data, clinical samples (blood,
urine, sputum and breath samples), lung function data and air pollution monitoring in their home. Multivariate
analysis will be used to identify the important risk factors contributing to the pneumonia burden in this setting.
Identification of preventable risk factors will justify research into the effectiveness of targeted interventions to
address this burden in the future.
Discussion: The AIR Study is the first study of radiologically confirmed pneumonia in which air pollution exposure
measurements have been undertaken in this setting, and will contribute important new information about exposure to
air pollution in urban SSA. Through identification of preventable risk factors, the AIR Study aims to facilitate future
research and implementation of targeted interventions to reduce the high burden of pneumonia in SSA.
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Background
Pneumonia is a leading cause of premature death world-
wide [1], and a common cause of adult admission to hos-
pital in sub-Saharan Africa (SSA) in both the pre- and
post-HIV eras [2, 3]. Adult pneumonia mortality in SSA
varies between 6 and 14.5 % [4–6], with over 50 % of
deaths in under 35 year olds [5].
Risk factors for developing pneumonia in affluent coun-
tries are well described but are less well understood in
countries like Malawi where HIV is known to be a major
contributing factor [7–9]. As HIV management improves
and living with HIV becomes life with a chronic dis-
ease, risk factors for pneumonia other than HIV will
become increasingly important. Poverty and crowded
living conditions have previously been identified as risk
factors for adult pneumonia in SSA [10, 11]. Many
other preventable exposures, including chronic respira-
tory disease (CRD), air pollution exposure, tobacco
smoke, malnutrition, excess alcohol and animal owner-
ship [12–22], may play a role but their relative import-
ance in SSA is uncertain.
With an ageing global population, there is a well recog-
nised emerging global epidemic of non-communicable
diseases, with the highest burden expected in SSA [23].
The burden of CRD - referring to any persistent disease of
the lower respiratory tract, including chronic obstructive
pulmonary disease (COPD), chronic bronchitis, bronchi-
ectasis, and asthma - is unknown in SSA [24] but expected
to be high, due to multiple interacting insults throughout
an individual’s lifetime, including maternal and childhood
malnutrition, recurrent respiratory tract infections, HIV,
tuberculosis (TB), air pollution exposures and tobacco
smoke.
According to the Global Burden of Disease Study,
tobacco smoke, indoor air pollution and outdoor air pollu-
tion are the 2nd, 4th and 9th leading global risk factors for
disability-adjusted life years (DALYs) respectively [24].
95 % of people in Malawi use unprocessed biomass fuels
(wood, charcoal, animal dung, crop residues) as their main
source of energy for essential household activities [26],
resulting in pollutant levels inside homes much greater
than the World Health Organisation (WHO) considers
safe [27]. Household air pollution (HAP) is a recognised
risk factor for childhood pneumonia [15], but the evidence
for adults is less conclusive: the Global Burden of Disease
study 2010 did not include estimates for this effect in their
analysis due to the lack of available evidence [25, 28]. Al-
though tobacco smoking is a well-recognised risk factor
for pneumonia in developed countries [17], very few stud-
ies in SSA have evaluated this association.
Pneumonia causes a major health burden in sub-
Saharan African adults, yet the risk factors for this are
poorly understood. This report outlines the protocol for a
study which aims to identify preventable risk factors
which will provide justification for targeted interventions,
to reduce the burden of disease seen. Robust data regard-
ing the association between inhalable pollutants and
adult pneumonia will inform health policy and ensure
appropriate allocation of resources towards interven-
tion strategies to reduce exposure: implementation of
air quality guidelines, indoor and outdoor pollution re-
duction and smoking prevention strategies. If an associ-
ation is demonstrated, strategies to prevent CRD could
not only help to reduce CRD, but may also impact on
the pneumonia burden.
The primary objectives of the study are:
 To determine the odds ratio of hospitalised adult
pneumonia by exposure to air pollution.
 To determine the odds ratio of hospitalised adult
pneumonia by the presence of CRD.
Methods/Design
Study design and setting
The Acute Infection of the Respiratory tract Study (the
AIR Study) is a case–control study set in Blantyre,
Malawi’s second largest city, where the urban population
has an estimated HIV prevalence of 17.4 %. Queen
Elizabeth Central Hospital (QECH), from where cases
will be recruited, is a large teaching hospital providing
healthcare to greater Blantyre (population approximately
1 million). Over 600 adult patients with pneumonia are
admitted to QECH per year and HIV prevalence in these
cases is approximately 70 %. Cases and controls will be
frequency matched by age and gender, and the study will
recruit subjects and analyse data within strata defined by
positive and negative HIV infection status. All partici-
pants will undergo assessment for CRD and detailed air
pollution exposure monitoring (indoor and outdoor) at
their homes.
Case definition
Cases will be recruited from QECH and defined by the
presence of the outcome of interest (pneumonia requiring
hospitalisation), using the inclusion and exclusion criteria
shown in Table 1.
Due to possible delays in obtaining chest x-rays for
some patients, individuals will be recruited if they meet
the other eligibility criteria prior to x-ray, and then will
be subsequently excluded if they do not have radiological
changes consistent with pneumonia.
Recruited individuals with pneumonia will be subse-
quently excluded as ‘case’ if they have died or commenced
anti-tuberculous treatment prior to completion of their
follow up assessment. These individuals will be excluded
from the final analysis but data will be retained for sub-
group analysis.
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Control definition
Controls will be recruited from the community and
defined by the absence of the outcome of interest (pneu-
monia requiring hospitalisation), using the inclusion and
exclusion criteria shown in Table 1.
Stratification and matching
Recruitment will be stratified by HIV status, which will en-
able data to be analysed as two separate cases-control
studies: a HIV-positive case–control sub-study, and a
HIV-negative case–control sub-study. Within these two
separate sub-studies, controls will be frequency matched
to cases by HIV age strata and gender. This will be done
by randomly selecting control within strata of matching
factors at a frequency determined by recent pneumonia
studies at QECH. Cases and controls will be recruited
concurrently in order to frequency match by season.
Matching factors will be controlled for in data analysis.
Study group recruitment
Case identification and recruitment
Adults admitted to QECH will be screened for symptoms
suggestive of pneumonia by study staff. Identified patients
and their case notes will be reviewed by the study clinical
officer or principal investigator for eligibility for the study.
Written informed consent from the patient or proxy con-
sent from their accompanying guardian will be obtained in
their first language.
Control identification and recruitment
Within Blantyre City, community controls will be ran-
domly selected by residential census enumeration area
(EA), where EAs are randomly chosen weighted by
population density. (EA boundary and population data
were obtained from National Office of Statistics,
Malawi). Random Global Positioning System (GPS)
starting points and vectors within the chosen neigh-
bourhoods will be generated and overlaid onto high
resolution satellite maps of Blantyre EAs using Google
Earth pro software. To identify controls, field workers
will start from the randomly generated GPS point, visit-
ing the first dwelling intersected by the randomly gen-
erated vector. All potential control participants in that
dwelling will be identified, screened for eligibility (in-
cluding age strata and gender) and asked for written
consent to perform a HIV test using a rapid diagnostic
test. Pre- and post-test counselling will be provided. In-
dividuals eligible for the study, will be asked to provide
written informed consent to join the study. Illiterate
participants will be consented in the presence of a literate
independent witness, who will countersign the partici-
pant’s thumbprint. Where multiple individuals within the
same household are eligible, an individual will be ran-
domly chosen for recruitment. A maximum of one indi-
vidual will be recruited per household.
If no one is home, dwellings will be visited up to three
times. Where an individual meeting eligibility criteria
has been identified but is not home, up to three at-
tempts to locate that individual will be made.
Table 1 Inclusion and exclusion criteria for cases and controls
Criteria for cases Criteria for controls
Inclusion Exclusion Inclusion Exclusion
Age 18 or over Pre-admission diagnosis of terminal
illness (e.g. metastatic malignancy,
terminal AIDS)
Age 18 or over Pre-existing diagnosis of terminal illness
(e.g. metastatic malignancy, terminal AIDS)
Lives in Blantyre city Current anti-TB treatment or
evidence of current TB infection
Lives in Blantyre
city
Current anti-TB treatment or evidence of
current TB infection
Reported cough or chest pain
or breathlessness or haemoptysis
Prior hospitalisation within the
last 4 weeks
Hospitalisation for a pneumonia-like illness
in the past 4 months or current
pneumonia-like illness
Reported fever or recorded fever
(≥38 °C)
Prior participation in the study Prior participation in the study
Crepitations or pleural rub
or bronchial breathing
or clinical features of pleural effusion
Lives in a residential institution
(eg. prison)
Lives in a residential institution (eg.
prison)
Radiological changes judged to be
new and consistent with pneumonia,
without another obvious cause
Death prior to follow up assessment Death prior to follow up assessment
Requires hospitalisation Alternative diagnosis explaining their
presentation
Utilises private health care facilities if has
illness requiring hospitalisation
Symptoms for 14 days or more
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The next dwelling intersected by the vector will then
be visited, and the process repeated. If the study team
reach the EA border, recruitment will stop and a new
randomly generated starting point within the same
residential neighbourhood will be used. Two controls
will be recruited from each EA, unless the EA has been
randomly chosen more than once.
The primary strategy for control recruitment, out-
lined above, will also be supplemented by recruitment
of HIV positive individuals from Anti-retroviral
Clinics at community Health Centres within Blantyre.
It is anticipated that approximately one third of HIV
positive controls will be recruited using this method
(approximately 50 individuals). This supplementary
method will be used to ensure that adequate numbers
of HIV positive controls will be recruited to the study,
as the above door-to-door method is resource inten-
sive and identification of HIV positive controls is chal-
lenging. The six health centres from across Blantyre
will be visited in rotation by study staff, and new and
existing patients at these clinics will be invited to
participate.
Study procedures
In-hospital assessment of cases
Initial assessment of cases will include:
 Medical history using questionnaires and case notes
 Clinical examination
○ blood pressure, pulse, temperature, respiratory
rate, oxygen saturations
○ height and weight (to calculate Body Mass
Index (BMI))
○ respiratory, cardiovascular and abdominal
examination
○ assessment of cognitive function
 Chest x-ray
 Blood culture
 Malaria rapid antigen test
 HIV testing and CD4 count
 Sputum specimen for tuberculous diagnostics -
smear fluorescent microscopy for acid-alcohol fast
bacilli, culture and GeneXpert®. If no spontaneous
sputum sample obtained, sputum induction using
nebulised hypertonic saline will be used when clin-
ically indicated.
 Diagnostic thoracocentesis (if pleural effusion is
present on chest x-ray and is clinically appreciable)
for tuberculous diagnostics - smear fluorescent mi-
croscopy for acid-alcohol fast bacilli and culture.
 BinaxNOW® Streptococcus pneumoniae urinary
antigen test
Exposure assessment in cases and controls
Exposure assessments will be made in the participant’s
home. Cases will undergo this assessment 2–4 months
following their admission for pneumonia (to allow
time to recover from their acute illness and return to
usual activities), and controls will be followed up
within 1–2 weeks of recruitment. Exposure assess-
ments will include:
 Questionnaires:
○ BOLD Questionnaires (Burden of Obstructive
Lung Disease Study, www.boldstudy.org) –
sections of the BOLD questionnaires will be
used to assess risk factors including
socioeconomic factors, chronic respiratory
symptoms, comorbidities and smoking history.
○ An additional questionnaire will be used to
assess other potential risk factors (including
indoor air pollution exposure, occupational
smoke exposures, contact with children /
people with illnesses, household conditions and
alcohol)
 Clinical measurements:
○ blood pressure, pulse, temperature, respiratory
rate, oxygen saturations
○ spirometry – pre- and post-bronchodilator
Forced Expiratory Volume in 1 s (FEV1) and
Forced Vital Capacity (FVC) will be measured
using an NDD EasyOne Spirometer according
to ATS/ERS guidelines [29]
▪ if spirometry is abnormal in cases then this
will be repeated following a 3–4 months period
to assess whether the abnormality is a chronic
or due to incomplete recovery from the
pneumonia episode.
○ sputum eosinophil counts will be assessed (in a
subsequent additional hospital visit) in a subset
of participants, using sputum induction with
nebulised hypertonic saline.
 Air pollution exposure assessment:
○ exhaled Carbon Monoxide (CO) measurement,
using a MicroCO monitor.
○ composite air pollution exposure monitoring:
▪ 48 h ambulatory for Particulate Matter
<2.5 μm in diameter (PM2.5) and CO
monitoring: participants will be asked to wear an
Aprovecho Indoor Air Pollution Meter in a
backpack for continuous monitoring.
▪ 48 h household PM2.5 and CO monitoring:
UCB-PATS (University of California, Berkeley -
Particle and Temperature Sensor) and Lascar
EL-USB-CO Data Logger monitors will be
placed in the participants kitchen or cooking
areas.
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During this follow up visit, controls will undergo the
following additional assessments (which have been
completed during the in-patient admission for cases):
 height and weight
 HIV test and CD4 count
 Sputum induction for tuberculous diagnostics if
chronic cough present suggestive of possible TB.
Exposure variables
Primary chronic respiratory disease exposure of interest
 A composite assessment of evidence of CRD,
defined by:
○ history of chronic respiratory symptoms in
keeping with COPD, bronchitis bronchiectasis
or asthma, as evidenced by one or both of the
following:
▪ answering in the affirmative to BOLD
questions regarding cough, phlegm, wheezing
or breathlessness.
▪ reporting a current diagnosis and treatment of
emphysema, asthma, asthmatic bronchitis,
allergic bronchitis, chronic bronchitis or
COPD (as per the BOLD questionnaire).
Primary air pollution exposure of interest
 A composite assessment of indoor and outdoor air
pollution exposure:
○ Area under the curve of personal PM2.5
exposure over a 48 h period
Secondary exposures and covariates of interest
 History of previous respiratory disease
 Area under the curve of personal CO exposure over
a 48 h period
 Mean/median and peak personal CO exposure over
a 48 h
 Mean/median and peak personal PM2.5 exposure
over a 48 h
 Area under the curve of household PM2.5 exposure
over a 48 h period
 Area under the curve of household CO exposure
over a 48 h period
 Mean/median and peak household CO exposure
over a 48 h
 Mean/median and peak household PM2.5 exposure
over a 48 h
 Self-reported air pollution exposures
○ Including HAP, occupational and tobacco
smoke exposure (personal and passive)
 HIV status, CD4 count, antiretroviral therapy use
 Spirometric evidence of obstruction or restriction
 Exhaled Carbon Monoxide






 Contact with children
 Contact with people with illnesses
 Animal ownership
 Marital status
Data collection, management and storage
Collection of data and storage will comply with Good
Clinical Practice guidelines as defined by the Inter-
national Conference on Harmonisation guidelines. All
questionnaire and examination data will initially be
collected on hard copy Case Report Forms (CRFs)
which will only be identifiable by a barcode containing
the participant’s unique study number. Intelligent
character recognition scanning software (Teleform®)
will be used to convert data into an electronic format.
Laboratory samples will be labelled with barcode and
study number, and results will be electronically trans-
ferred to the study database. Air pollution monitoring
data will be downloaded directly from the monitoring
equipment for analysis with the relevant software. Chest
x-ray films will be captured by digital photograph, and will
be stored anonymously for radiological analysis.
CRFs will be stored in locked filling cabinets within
MLW, only accessible to the study team and the MLW
data management group. All electronic data will be
exported to a database on the secure MLW server. Data
files will be exported to Stata 13.1 (Statacorp, USA) for
analysis. Access to the study database will be password-
protected and restricted to the principal investigator,
study investigators, and study data manager. Analysis of
anonymised electronic data will be performed by the
principal investigator, with support from co-investigators
and the study statistician.
Quality control
To ensure delivery of a high quality study, the following
measures will be taken:
 Standardised methodology will be employed for
participant recruitment and data collection, and
Standard Operating Procedures will be followed for
all necessary procedures.
 All study workers will be provided with study-
specific training prior to study commencement and
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performance will be monitored throughout the
study.
 Spirometry will be performed by individuals who are
certified to perform spirometry to international
standards.
 All study workers will complete GCP training prior
to study commencement.
 All equipment will be regularly calibrated in line
with manufacturer’s recommendations.
 Spirometry tracing and radiology will be reviewed





 Percentage of controls with exposure of interest (eg.
CRD) 15–50 %
 α = 0.05
 β = 0.02
The target sample sizes for exposure assessment in the
two sub-studies are:
 HIV-positive sub-study (case:control ratio 1:1) to
detect an odds ratio of 1.9–2.2:
○ Cases 160
○ Controls 160
 HIV-negative sub-study (case:control ratio 1:1.5) to
detect an odds ratio of 2.7–3.0:
○ Cases 60
○ Controls 90
Up to 50 % of recruited cases are expected to be
excluded following recruitment but prior to follow up
(due to lack of radiological pneumonia, deaths and com-
mencing TB treatment). To account for this expected
loss to follow up, the total recruitment targets to achieve




HIV is expected to have a large impact on the outcome,
and potential interactions between HIV and other risk
factors for pneumonia may exist. Within the resource
constraints of this study, it is unlikely that this study will
be adequately powered to explore these interactions.
The study will therefore be analysed as two separate
case–control studies; a HIV-positive study and a HIV-
negative study.
Univariate comparisons between groups will be made
for explanatory variables using two-sample t-tests or
Mann–Whitney tests for continuous data or Pearson’s
Chi-square / Fisher’s exact testing for categorical data
(p ≤0.05 will be considered statistically significant).
Correlations between continuous explanatory variables
will be tested for using Pearson’s or Spearman’s rank
correlation tests. Explanatory variables that are associ-
ated with pneumonia with a p value of less than 0.2 will
be eligible for inclusion in a multivariate regression
model. An unconditional logistic regression model will
be developed using a stepwise forward selection ap-
proach (criteria for entry p < 0.05 and removal p < 0.1),
to identify risk factors for pneumonia incorporating ad-
justment for potential confounders as well as matching
factors (matching factors will be treated as nuisance pa-
rameters and their coefficients will not be reported).
Interaction terms of interest will be tested prior to fina-
lising the model. The assumptions of the model will be
tested by examination of the residuals, and the overall fit
of the model will be ascertained using the Hosmer and
Lemeshow goodness-of-fit model.
Structural equation modelling will be carried out to en-
able assessment of causal pathways and confounding. This
methodology enables a quantitative estimation of relation-
ships between the predictor variables, as well as between
the predictor variables and the outcome variable.
Sensitivity analyses will be performed, to assess for
the effects of exclusion of individuals who did not sur-
vive and inclusion of cases with multiple episodes of
hospitalised pneumonia.
A comparison of characteristics between the controls
recruited by the primary strategy (household recruit-
ment) and the supplementary strategy (clinic recruit-
ment) will be made. If significant differences are found,
a sensitivity analysis will be performed to assess the
effects of this on the findings.
Secondary analyses will explore risk factors for pneu-
monia severity within cases.
Ethical considerations
This study will be carried out to include the protection
of human subjects according to the 2008 Declaration of
Helsinki and in accordance with Good Clinical Practice
guidelines. Informed consent will be obtained from all
study participants (or their guardian) in their first lan-
guage, either written or witnessed verbal consent if the
participant (or guardian) is illiterate. A substantial pro-
portion of hospitalized pneumonia patients may not be
able to provide informed consent at initial assessment
due to confusion or clinical instability. Acutely con-
fused/obtunded patients will be initially recruited on the
basis of proxy consent expressed by an accompanying
guardian and formal informed consent will be requested
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when the participant has recovered to the extent that
they are able to have reasonable comprehension and
retention of the information related to the study.
The main burden for participants is the time and in-
convenience of follow up visits at their home. There
are also some small risks to the participants from some
of the clinical investigations that will be performed (in
particular, thoracocentesis, and spirometry) but strict
safety guidelines will be followed and will only be per-
formed when no contraindications are present. Study
participants will be offered a small gift (up to the value
of $4 USD) to compensate them for the time taken and
inconvenience of participating in the study.
This study has been approved by the College of Medi-
cine Research Ethics Committee, University of Malawi
and the Liverpool School of Tropical Medicine Research
Ethics Committee.
Discussion
Pneumonia is a leading cause of morbidity and mortality
in SSA. The AIR Study provides a unique opportunity to
study the risk factors for developing pneumonia in a
population of individuals in urban Malawi who are care-
fully characterised during their hospital admission.
The AIR Study is the first study of radiologically con-
firmed pneumonia in which air pollution exposure mea-
surements have been undertaken in this setting. Although
these measurements are limited to a 48 hour snapshot,
the measurement of both ambulatory and household CO2
and PM2.5, combined with detailed exposure question-
naires, will contribute important new information about
exposure to air pollution in urban SSA.
Through use of already established symptom burden
questionnaires for CRD (BOLD questionnaires) and spir-
ometry performed according to ATS/ERS guidelines, the
AIR study will provide data that will allow comparison of
the burden of CRD across other parts of SSA and further
afield, as well as being able to robustly address the primary
objective of assessing the contribution of CRD to pneu-
monia burden. Through identification of preventable risk
factors, the AIR Study aims to facilitate future research
and implementation of targeted interventions to reduce
the high burden of pneumonia in SSA.
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